BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Aug. 28, 2007
View Archived Issues
Neurochem Slides 43 Percent On Alzhemed Phase III Failure
After six months of number crunching, Neurochem Inc. confirmed what most analysts already suspected: the North American Phase III trial of Alzhemed (tramiprosate) in Alzheimer's disease did not meet its primary endpoints. (BioWorld Today)
Read More
FDA Sends IDM's Junovan Back For More Trial Data
Read More
Stem Cell Transplants Give Hope For Bedside, Lessons For Bench
Read More
BioLineRx Gets BL-4040 Rights; Delves Into Acute Kidney Injury
Read More
Upstream Completes Acquisition Of Firm Focused On Parasites
Read More
Financings Roundup
Read More
Other News To Note
Read More
Clinic Roundup
Read More